Artiva Biotherapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 29, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 29, 2024
ARTV$4.22+1.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and par value data)
| AS OF | ||
|---|---|---|
| JUNE 30,2024 | DECEMBER 31,2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $34,248 | $53,504 |
| Short-term investments | 12,308 | 23,467 |
| Accounts receivable (including related party amounts of $569 and $569, respectively) | 569 | 1,034 |
| Other receivables (including related party amounts of $700 and $607, respectively) | 892 | 724 |
| Prepaid expenses and other current assets | 1,732 | 1,092 |
| Total current assets | 49,749 | 79,821 |
| Restricted cash | 258 | 258 |
| Property and equipment, net | 7,315 | 8,096 |
| Operating lease right-of-use assets | 15,129 | 16,547 |
| Financing lease right-of-use asset | 291 | — |
| Deferred offering costs | 2,840 | — |
| Other long-term assets | 330 | 392 |
| Total assets | $75,912 | $105,114 |
| Liabilities, convertible preferred stock, and stockholders’ deficit | ||
| Current liabilities: | ||
| Accounts payable (including related party amounts of $223 and $199, respectively) | $823 | $614 |
| Accrued expenses (including related party amounts of $859 and $2,161, respectively) | 6,214 | 8,017 |
| Current portion of operating lease liabilities | 3,674 | 3,596 |
| Current portion of financing lease liability | 116 | — |
| Total current liabilities | 10,827 | 12,227 |
| Operating lease liabilities, net of current portion | 11,869 | 13,316 |
| Financing lease liability, net of current portion | 106 | — |
| Simple agreements for future equity (“SAFEs”) (including related party amounts of $22,427 and $20,315, respectively) | 27,720 | 25,100 |
| Other non-current liabilities | 74 | 73 |
| Total liabilities | 50,596 | 50,716 |
| Commitments and contingencies (Note 11) | ||
| Series A convertible preferred stock, $0.0001 par value; 16,110,463 shares authorized; 3,673,148 issued and outstanding at June 30, 2024 and December 31, 2023; $80,552 aggregate liquidation preference at June 30, 2024 and December 31, 2023 | 96,767 | 96,767 |
| Series B convertible preferred stock, $0.0001 par value; 10,909,091 shares authorized, 2,487,237 shares issued and outstanding at June 30, 2024 and December 31, 2023; $120,000 aggregate liquidation preference at June 30, 2024 and December 31, 2023 | 119,646 | 119,646 |
| Stockholders’ deficit: | ||
| Common stock, $0.0001 par value; 40,248,588 and 38,998,588 shares authorized at June 30, 2024 and December 31, 2023, respectively; 814,202 and 809,758 shares issued and outstanding at June 30, 2024 and December 31, 2023 | — | — |
| Additional paid-in capital | 21,899 | 18,988 |
| Accumulated other comprehensive income | 121 | 308 |
| Accumulated deficit | (213,117) | (181,311) |
| Total stockholders’ deficit | (191,097) | (162,015) |
| Total liabilities, convertible preferred stock and stockholders’ deficit | $75,912 | $105,114 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.